Streetbeat News

Equity Actions

ZYXI

Zynex's Board of Directors has approved a program to repurchase up to $20M of the company's common stock.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:30 pm

IBIO

iBio, Inc. (IBIO) has announced the expansion of its AI-powered technology stack with the launch of ShieldTx, a patent-pending antibody masking technology. This technology is designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue. The company used ShieldTx to develop masks for its MUC16-targeted bispecific antibody candidates, which were previously developed using iBio's patented Epitope Steering and EngageTx™ AI Platforms. The new technology could potentially increase the safety and developability of therapeutic antibodies for difficult targets and modes of action.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:29 pm

FTDR

Frontdoor has raised its full-year 2023 outlook, increasing its revenue range to $1.765 billion to $1.775 billion, gross profit margin range to 48.0% to 49.5%, and Adjusted EBITDA range to $320 million to $330 million. The company also increased its 2023 share repurchase outlook to $125 million.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:27 pm

CDAY

Ceridian (NYSE:CDAY) announced that Co-CEO Leagh Turner will leave the company on November 10, 2023, to become CEO of Coupa Software. David Ossip will continue as the sole CEO. Turner joined Ceridian in 2018 and was appointed as Co-CEO in 2022. During her tenure, she helped double the company's revenue and increase the Dayforce customer base to over 6,300 live customers. The company will discuss the change during its third quarter financial results call.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:24 pm

OCUP

Ocuphire Pharma, Inc. (NASDAQ:OCUP) has appointed George Magrath as its new CEO and member of the Board of Directors. Magrath, who has extensive experience in the pharmaceutical industry, succeeds Rick Rodgers, who has been serving as Interim CEO since April 2023. Magrath was previously the CEO of Lexitas Pharmaceutical Services, where he led significant growth and increased revenue. He will lead Ocuphire in advancing the clinical development of its lead retina asset, APX3330.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:24 pm

DERM

JSPR

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has appointed Thomas G. Wiggans, a veteran biopharmaceutical executive, as Chairperson of its Board of Directors. Wiggans has served in senior leadership positions at multiple successful biopharmaceutical companies, including Dermira (NASDAQ:DERM), which was acquired by Eli Lilly in 2020. The current Chairperson, Bill Lis, will retire from the Board in December.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:17 pm

CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) has appointed Monica Tellado as President, Emerging Markets. Tellado, who previously served as CFO at Heartflow and held various leadership roles at Gilead Sciences, will report to Corcept's CEO and join the company's Executive Team. She will serve as the global commercial lead for therapeutics in metabolism and neurology and oversee pipeline and portfolio planning activities across the company's other therapeutic areas.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:17 pm

SPRO

Spero Therapeutics has announced the appointment of Esther Rajavelu as its new CFO and Chief Business Officer. She will be succeeding Stephen Dipalma, who has been serving as the company's interim CFO since August 1, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:13 pm

MOTS

Motus GI has announced a 1-for-15 reverse stock split, which will begin trading on a split-adjusted basis from November 2.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:04 pm

VTVT

vTv Therapeutics Inc. (NASDAQ:VTVT) has sold all of its common stock in Reneo Pharmaceuticals for approximately $4.4 million. The proceeds will support vTv's preparations for the launch of the cadisegliatin Phase 3 program in type 1 diabetes. vTv remains eligible to receive up to $94.5 million in milestones, as well as royalties on potential sales of products under the Reneo license agreement.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:02 pm